Advanced Asset Management Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Advanced Asset Management Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,000	Closed	-$973K	–	132
2018 Q3	$973K	Hold	7,000	–	–	0.35%	56
2018 Q2	$869K	Hold	7,000	–	–	0.28%	74
2018 Q1	$780K	Hold	7,000	–	–	0.26%	77
2017 Q4	$837K	Buy	+7,000	New	+$852K	0.28%	72

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Advanced Asset Management Advisors's ALXN Position: Q4 2018 in Review

Advanced Asset Management Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 7,000 shares — an estimated $973K sold.

Advanced Asset Management Advisors first reported a position in ALXN in Q4 2017 and held it in 4 quarters. The position peaked at $973K in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Advanced Asset Management Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Advanced Asset Management Advisors sold 7,000 Alexion Pharmaceuticals shares in Q4 2018, an estimated $973K.
Advanced Asset Management Advisors first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Advanced Asset Management Advisors's Alexion Pharmaceuticals position peaked at $973K in Q3 2018.
608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Advanced Asset Management Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.